PTO/SB/21 (09-04) Approved for use through 07/31/2006, OMB 0851-003 (U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/642970 Filing Date TRANSMITTAL August 18, 2003 RECEIVED CENTRAL FAX CENTER First Named Inventor FORM Olaf RITZELER et al. Art Unit 1624 DEC 2 0 2005 Examiner Name RAO, Deepak R. (to be used for all correspondence after initial filing) Attorney Docket Number 'DEAV2002/0063 US NP Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittel Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) V Petition Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below): Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD **Gerlified Copy of Priority** Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name ITIS PHARMACEUTICALS INC. Signature Printed name Reg. No. Date 47,038 mber 20, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 ; Total No. of Pages Transmitted: 13 Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

December 20, 2005

Paul Irvine

Typed or printed name

DEAV2002/0063 US NP

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of RITZELER, et al.

Application No.: 10/642,970

Examiner:

D. Rao

BECEIVER

Filed:

August 18, 2003

Art Unit:

1624

DEC 2 0 2005

Title:

Indole Derivatives or Benzimidazole

Derivatives for Modulating IkB Kinase

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

Date of Transmission

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

REPLY PURSUANT TO 37 CFR § 1.111

This paper is a Reply to the Action dated September 27, 2005 pursuant to 37 C.F.R. § 1.111 in connection with the above-identified patent application. Applicants respectfully request that the application be amended, without prejudice, as follows:

- Amendments to the claims are reflected in the Listing of Claims, which begins 冈 on page 2 of this paper.
- 冈 Remarks/Arguments begin on page 10 of this paper.